Performance
Is Muscle Loss Normal with Fibroids?
Uterine fibroids are usually discussed in terms of bleeding and pain — but they also create a hormonal and metabolic environment that actively degrades muscle tissue. Understanding why muscle loss happens with fibroids is the first step to stopping it.
Is Muscle Loss Normal with Fibroids?
Yes, muscle loss is a real and underappreciated consequence of living with uterine fibroids — though it is not inevitable. The primary drivers are estrogen dominance (which shifts protein metabolism away from muscle synthesis), chronic iron deficiency from heavy menstrual bleeding, and systemic inflammation that raises catabolic signaling. Women with well-managed fibroids and adequate nutrition often preserve muscle mass; those with heavy bleeding or significant hormonal imbalance are at the highest risk.
---
Why Fibroids Affect More Than Your Uterus
Uterine fibroids (uterine leiomyomas) are benign smooth-muscle tumors that affect an estimated 70–80% of women by age 50, with higher prevalence and earlier onset in Black women (Stewart et al., American Journal of Obstetrics and Gynecology 2017; PMID: 27743500). Most conversations about fibroids center on pain, pressure, and abnormal bleeding — but the systemic metabolic consequences rarely get the same airtime.
Fibroids create a hormonal environment skewed toward estrogen. High estrogen relative to progesterone does several things that matter for muscle: it can suppress insulin-like growth factor-1 (IGF-1) signaling, impair satellite cell activation, and upregulate myostatin — a protein that actively inhibits muscle fiber growth (Dieli-Conwright et al., Journal of Clinical Endocrinology & Metabolism 2009; PMID: 19820018). Meanwhile, heavy menstrual bleeding leads to iron-deficiency anemia, which reduces oxygen delivery to working muscle and severely blunts exercise tolerance and recovery.
This combination — catabolic hormonal signaling plus impaired oxygen transport — sets the stage for measurable lean mass decline, particularly if activity levels drop because exercise becomes painful or exhausting.
For women managing related hormonal conditions, the picture can be even more complex. Muscle loss with adenomyosis follows a nearly identical hormonal pathway, and the two conditions frequently co-occur.
---
The Iron-Muscle Connection Most Women Miss
Iron is not just a blood metric — it is a mitochondrial necessity. Iron-sulfur clusters within the electron transport chain require adequate iron to produce ATP efficiently. When iron stores fall, mitochondrial output drops even before hemoglobin levels flag anemia on a standard CBC.
A review in Nutrition Reviews found that iron-deficiency anemia reduces aerobic capacity by up to 30% and impairs skeletal muscle oxidative function independent of hemoglobin levels (Haas & Brownlie, Nutrition Reviews 2001; PMID: 11475448). In practical terms, this means a woman with fibroids-induced heavy bleeding may feel too fatigued to train effectively, lose the anabolic stimulus that exercise provides, and drift into a net catabolic state — all while her doctors focus on managing the bleeding rather than the downstream muscle consequences.
Restoring iron to optimal — not just to the bottom of the reference range — is therefore a foundational intervention. Ferritin targets of 50–100 ng/mL are commonly cited by sports medicine practitioners as the threshold at which training capacity and recovery normalize. Without achieving that level, even a structurally sound resistance-training program will underdeliver on muscle retention.
It is also worth noting that myoglobin, the protein that stores and releases oxygen directly within muscle fibers, is itself iron-dependent. Depleted myoglobin stores reduce the muscle's ability to sustain aerobic effort locally, compounding the systemic effects of low hemoglobin. Women with fibroids who report feeling muscularly weak even at low exercise intensities are often experiencing exactly this dual impairment.
---
Inflammation, Cytokines, and Muscle Protein Breakdown
Fibroids are not metabolically inert tumors. Active leiomyomas secrete pro-inflammatory cytokines — particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) — that have well-characterized catabolic effects on skeletal muscle. TNF-α in particular activates the ubiquitin-proteasome pathway, the cell's primary system for degrading damaged or surplus proteins, leading to accelerated muscle protein breakdown even when dietary protein intake is adequate (Reid & Li, Journal of Applied Physiology 2001; PMID: 11641358).
IL-6, while acutely anabolic when produced transiently during exercise, becomes catabolic in the chronically elevated state seen in inflammatory conditions. Chronically elevated IL-6 promotes the expression of suppressor-of-cytokine-signaling (SOCS) proteins that blunt anabolic insulin and IGF-1 receptor signaling, creating a state of anabolic resistance — meaning that even if a woman eats adequate protein and trains consistently, her muscle fibers respond less efficiently to those stimuli.
This inflammatory burden also intersects with cortisol. Chronic inflammation upregulates the hypothalamic-pituitary-adrenal (HPA) axis. Elevated cortisol increases muscle protein catabolism by suppressing mTORC1 signaling — the master regulator of muscle protein synthesis — and by increasing the rate at which amino acids are shunted toward gluconeogenesis rather than muscle repair (Schakman et al., Journal of Endocrinology 2008; PMID: 18653616). Women with large or symptomatic fibroids, chronic pelvic pain, and disrupted sleep are often running in a high-cortisol state without realizing it.
For context on how this inflammatory-hormonal cascade plays out in other hormone-driven conditions, the pattern described in what causes muscle loss with fibroids maps closely onto mechanisms seen across endometriosis and PCOS as well — conditions where estrogen dominance and systemic inflammation co-exist.
---
Who Is at Highest Risk of Muscle Loss with Fibroids?
Not every woman with fibroids will experience clinically significant muscle loss. Risk is higher when several variables stack together:
- Heavy menstrual bleeding (HMB): Losing more than 80 mL of blood per cycle (a common threshold for HMB) can deplete iron stores within 2–3 cycles, initiating the anemia-fatigue-deconditioning spiral described above.
- Large or multiple fibroids: Larger tumors appear to produce more inflammatory cytokines and may exert mechanical pressure that restricts comfortable movement, reducing daily activity and the anabolic signal it provides.
- Concurrent low vitamin D: Vitamin D receptors are expressed on muscle cells, and insufficiency (<30 ng/mL) is independently associated with lower muscle fiber diameter and reduced muscle function. Fibroids are more prevalent in women with low vitamin D, creating a compounding risk (Baird et al., Epidemiology 2013; PMID: 23249637).
- Perimenopause with fibroids: As estrogen fluctuates and progesterone declines during perimenopause, fibroids can temporarily enlarge. At the same time, the natural decline in anabolic hormone levels accelerates sarcopenia risk. Muscle loss in perimenopause with hypothyroidism explores how these overlapping hormonal shifts compound the problem.
- Sedentary baseline: Women who were already lightly active before fibroid symptoms worsened have less muscle reserve to draw from when catabolism increases.
The exception — women who appear largely protected — tends to share a profile: iron levels maintained in the optimal range, high dietary protein intake (1.6–2.0 g/kg body weight daily), consistent resistance training, and either well-controlled fibroid burden or post-treatment recovery.
---
Practical Protocol: Protecting Muscle When You Have Fibroids
Because muscle loss with fibroids is multifactorial, the intervention has to be equally multifactorial. A single supplement or a single dietary tweak will not offset the combined pressure of hormonal disruption, iron depletion, and chronic inflammation.
Nutrition Priorities
- Protein: Target 1.6–2.0 g per kg of body weight daily. Distribute intake across at least three meals; no single meal should carry more than ~40 g of protein if absorption efficiency is a concern. Leucine-rich sources (eggs, dairy, poultry, legumes combined with grains) are preferable because leucine directly activates mTORC1.
- Iron: Pair iron-rich foods with vitamin C sources to enhance non-heme iron absorption. Avoid tea or coffee within 60 minutes of iron-rich meals — polyphenols chelate iron and can reduce absorption by 60–70%.
- Anti-inflammatory foods: An eating pattern emphasizing oily fish, colorful vegetables, and extra-virgin olive oil reduces circulating IL-6 and TNF-α over time, blunting the cytokine-driven catabolism described above.
Exercise Priorities
- Resistance training 2–3×/week: Even two sessions per week of compound resistance exercise is sufficient to maintain mTORC1 activation and preserve lean mass during periods of elevated catabolism.
- Avoid overreaching: In the context of systemic inflammation and possible anemia, very high training volumes can raise cortisol disproportionately. Moderate intensity with adequate recovery is more protective than high-volume training when the body is under inflammatory load.
- Low-impact aerobic activity: Walking, cycling, or swimming on non-resistance days supports mitochondrial health and insulin sensitivity without the cortisol spike of high-intensity cardio.
Monitoring
| Biomarker | Optimal Target | Why It Matters for Muscle |
|---|---|---|
| Ferritin | 50–100 ng/mL | Supports mitochondrial ATP production and myoglobin |
| Hemoglobin | ≥12 g/dL (women) | Adequate oxygen delivery to working muscle |
| 25-OH Vitamin D | 40–60 ng/mL | Muscle fiber diameter and neuromuscular function |
| hsCRP | <1.0 mg/L | Low inflammation = less cytokine-driven catabolism |
| IGF-1 | Age-appropriate mid-range | Reflects anabolic hormone environment |
Tracking these markers over time — ideally every 3–6 months — allows you to intervene before lean mass loss becomes clinically significant.
Women navigating related conditions may find it useful to read about muscle loss during a heavy period and muscle loss in postmenopause for context on how similar mechanisms operate at different reproductive stages.
---
What This Means for Your Formula
Fibroids-related muscle loss is driven by three interlocking issues: hormonal disruption, iron-mediated energy deficiency, and chronic inflammation. A personalized supplement formula needs to address all three — not just offer a generic protein-boosting stack.
Ones builds custom capsule formulas by analyzing lab results, wearable data, and health history through an AI health practitioner. For someone whose data reflects the fibroid-related pattern — low ferritin, elevated inflammatory markers, low vitamin D, disrupted sleep — several ingredients from the Ones catalog are directly relevant:
- Vitamin D3 + K2 (MK-7): Clinical trials support vitamin D supplementation for improving muscle fiber size and reducing fall risk in deficient populations (Bischoff-Ferrari et al., JAMA 2004; PMID: 15199032). K2 as MK-7 supports the routing of calcium into bone rather than soft tissue, complementing D3's musculoskeletal effects. Ones includes both in a single combined ingredient.
- Magnesium Glycinate (from Ones' Magnesium Complex): Magnesium is a cofactor in over 300 enzymatic reactions, including those governing ATP synthesis and muscle protein synthesis initiation. Deficiency — common in women with elevated cortisol and poor sleep — directly impairs muscle recovery.
- Adrenal Support System Blend: For women in a chronic cortisol-elevated state driven by pain, poor sleep, and inflammatory burden, supporting HPA axis regulation is critical. Ones' Adrenal Support blend is designed to moderate the catabolic cortisol-muscle axis without sedation.
The AI-driven approach means that if your lab work shows optimal ferritin but low D and elevated hsCRP, your formula addresses those specific gaps — rather than delivering a generic multi that spreads low doses across dozens of ingredients and achieves clinical effect in none of them.
---
Key Takeaways
- Muscle loss with fibroids is real but not universal — it is most severe when heavy bleeding causes iron deficiency and when inflammatory cytokines are chronically elevated.
- Estrogen dominance suppresses IGF-1 and activates myostatin, shifting the protein metabolism balance toward catabolism.
- Iron depletion impairs mitochondrial ATP production and myoglobin function, reducing both exercise capacity and the anabolic stimulus that maintains muscle.
- TNF-α and IL-6 secreted by active fibroids activate muscle protein breakdown pathways and create anabolic resistance, making the muscle less responsive to protein and training.
- The highest-risk profile combines heavy menstrual bleeding, low vitamin D, sedentary lifestyle, and concurrent perimenopause.
- A practical protection strategy centers on optimal ferritin (50–100 ng/mL), high dietary protein (1.6–2.0 g/kg/day), consistent resistance training, and targeted supplementation based on your specific lab data — not a one-size-fits-all stack.
Always consult a qualified healthcare provider before starting any new supplement protocol, particularly if you are managing an active medical condition such as uterine fibroids.